HIV Protease Inhibitors Promote Atherosclerotic Lesion Formation Independent of Dyslipidemia by Increasing CD36-Dependent Cholesteryl Ester Accumulation in Macrophages by Dressman, James et al.
University of Kentucky 
UKnowledge 
Physiology Faculty Publications Physiology 
2-2003 
HIV Protease Inhibitors Promote Atherosclerotic Lesion 
Formation Independent of Dyslipidemia by Increasing 
CD36-Dependent Cholesteryl Ester Accumulation in Macrophages 
James Dressman 
University of Kentucky 
Jeanie Kincer 
University of Kentucky, jeanie.kincer@uky.edu 
Sergey V. Matveev 
University of Kentucky, sergey.matveev@uky.edu 
Ling Guo 
University of Kentucky, ling.guo@uky.edu 
Richard N. Greenberg 
University of Kentucky, rngree01@uky.edu 
See next page for additional authors 
Follow this and additional works at: https://uknowledge.uky.edu/physiology_facpub 
 Part of the Infectious Disease Commons, Medical Nutrition Commons, and the Physiology Commons 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Repository Citation 
Dressman, James; Kincer, Jeanie; Matveev, Sergey V.; Guo, Ling; Greenberg, Richard N.; Guerin, Theresa; 
Meade, David; Li, Xiang-An; Zhu, Weifei; Uittenbogaard, Annette M.; Wilson, Melinda E.; and Smart, Eric J., 
"HIV Protease Inhibitors Promote Atherosclerotic Lesion Formation Independent of Dyslipidemia by 
Increasing CD36-Dependent Cholesteryl Ester Accumulation in Macrophages" (2003). Physiology Faculty 
Publications. 176. 
https://uknowledge.uky.edu/physiology_facpub/176 
This Article is brought to you for free and open access by the Physiology at UKnowledge. It has been accepted for 
inclusion in Physiology Faculty Publications by an authorized administrator of UKnowledge. For more information, 
please contact UKnowledge@lsv.uky.edu. 
HIV Protease Inhibitors Promote Atherosclerotic Lesion Formation Independent 
of Dyslipidemia by Increasing CD36-Dependent Cholesteryl Ester Accumulation in 
Macrophages 
Digital Object Identifier (DOI) 
https://doi.org/10.1172/JCI16261 
Notes/Citation Information 
Published in The Journal of Clinical Investigation, v. 111, no. 3. 
© 2003 The American Society for Clinical Investigation 
The copyright holder has granted the permission for posting the article here. 
Authors 
James Dressman, Jeanie Kincer, Sergey V. Matveev, Ling Guo, Richard N. Greenberg, Theresa Guerin, 
David Meade, Xiang-An Li, Weifei Zhu, Annette M. Uittenbogaard, Melinda E. Wilson, and Eric J. Smart 
This article is available at UKnowledge: https://uknowledge.uky.edu/physiology_facpub/176 
HIV protease inhibitors promote atherosclerotic lesion formation
independent of dyslipidemia by increasing CD36-dependent
cholesteryl ester accumulation in macrophages
James Dressman, … , Melinda E. Wilson, Eric J. Smart
J Clin Invest. 2003;111(3):389-397. https://doi.org/10.1172/JCI16261.
 
Protease inhibitors decrease the viral load in HIV patients, however the patients develop hypertriglyceridemia,
hypercholesterolemia, and atherosclerosis. It has been assumed that protease inhibitor–dependent increases in
atherosclerosis are secondary to the dyslipidemia. Incubation of THP-1 cells or human PBMCs with protease inhibitors
caused upregulation of CD36 and the accumulation of cholesteryl esters. The use of CD36-blocking antibodies, a CD36
morpholino, and monocytes isolated from CD36 null mice demonstrated that protease inhibitor–induced increases in
cholesteryl esters were dependent on CD36 upregulation. These data led to the hypothesis that protease inhibitors
induce foam cell formation and consequently atherosclerosis by upregulating CD36 and cholesteryl ester accumulation
independent of dyslipidemia. Studies with LDL receptor null mice demonstrated that low doses of protease inhibitors
induce an increase in the level of CD36 and cholesteryl ester in peritoneal macrophages and the development of
atherosclerosis without altering plasma lipids. Furthermore, the lack of CD36 protected the animals from protease
inhibitor–induced atherosclerosis. Finally, ritonavir increased PPAR-γ and CD36 mRNA levels in a PKC- and PPAR-γ–
dependent manner. We conclude that protease inhibitors contribute to the formation of atherosclerosis by promoting the
upregulation of CD36 and the subsequent accumulation of sterol in macrophages.
Article AIDS/HIV
Find the latest version:
https://jci.me/16261/pdf
Introduction
The Swiss HIV Cohort Study established a definite link
between HIV protease inhibitors and dyslipidemia (1).
HIV protease inhibitor–induced dyslipidemia is char-
acterized primarily by elevations in plasma triglyceride
levels and (to a lesser extent) plasma cholesterol levels
(1–4). Stein et al. (5) documented that HIV protease
inhibitors promote the formation of atherogenic
lipoproteins and endothelial dysfunction. In addition,
a recent report by Tabib et al. (6) documents accelerat-
ed coronary atherosclerosis and arteriosclerosis in
young HIV-positive patients. This has led to the sup-
position that HIV protease inhibitor–induced dyslipi-
demia is a significant clinical concern and may con-
tribute to accelerated atherosclerotic plaque formation
(7–9). However, multiple mechanisms are involved in
the initiation, progression, and rupture of atheroscle-
rotic lesions (10–12), and although elevated plasma
triglyceride and cholesterol levels are an important
component of the disease process, these lipid factors
fail to account for a significant number of clinically rel-
evant atherosclerotic lesions, thereby indicating that
other mechanisms must be involved (13).
The generation of lipid-laden macrophages is a key
event in atherogenesis and is thought to be due in part
to unregulated uptake of modified lipoproteins (14,
15). Aberrant sterol accumulation is influenced by scav-
enger receptors such as CD36 (16, 17). The exact role of
CD36 in the development of atherosclerotic lesions is
unclear; however, a natural polymorphism in the CD36
gene in humans indicates that CD36 is likely to be an
important receptor for the metabolism of lipoprotein
in vivo (18). Monocytes/macrophages obtained from
patients with a CD36 polymorphism bound less oxi-
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dized LDL and accumulated less sterol than did con-
trol patients (19). Recent studies with CD36 null mice
have confirmed the initial human findings and demon-
strated that the presence of CD36 in macrophages pro-
motes the accumulation of sterol and the formation of
atherosclerotic lesions (16, 17).
To date the direct effects of HIV protease inhibitors
on macrophage sterol accumulation have not been
studied. The present studies use both in vitro and in
vivo models to demonstrate that HIV protease
inhibitors induce a specific increase in macrophage
CD36 levels and that this promotes an increase in the
accumulation of macrophage cholesteryl ester and ath-
erosclerotic lesion formation. More importantly, the
data demonstrate that HIV protease inhibitors can
increase atherosclerotic lesion formation independent
of frank dyslipidemia. The importance of these find-
ings with regard to the therapeutic treatment of
patients with HIV protease inhibitors is discussed.
Methods
Materials. RPMI 1640, DMEM high glucose medium,
FCS, L-glutamine, trypsin-EDTA, penicillin-strepto-
mycin, and OptiPrep were purchased from Life Tech-
nologies Inc. (Grand Island, New York, USA). Percoll,
PVDF membrane, and Tween 20 were purchased from
Sigma-Aldrich (St. Louis, Missouri, USA). Bradford
reagent was purchased from BioRad Laboratories (Her-
cules, California, USA). The analytical silica gel TLC
plates, heptane, petroleum ether, ethyl ether, acetic
acid, and 2-propanol were from Fisher Scientific Co.
(Pittsburgh, Pennsylvania, USA). [3H]acetate (specific
activity 5.11 Ci/mmol) was from DuPont NEN Life 
Science Products (Boston, Massachusetts, USA).
Anti–caveolin-1 IgG was obtained from BD Biosciences
(San Diego, California, USA), anti-actin IgG was from
Sigma-Aldrich, anti–mouse CD36 (IgM) was from
BioDesign International Inc. (Kennebunkport, Maine,
USA), and anti–scavenger receptor A (anti-SRA) was
from Serotec Ltd. (Raleigh, North Carolina, USA) HRP-
conjugated IgG’s were supplied by Organon Teknika
Corp. USA (West Chester, Pennsylvania, USA). Super
Signal chemiluminescent substrate was purchased
from Pierce Chemical Co. (Rockford, Illinois, USA).
The analytical silica gel TLC plates, heptane, petroleum
ether, ethyl ether, acetic acid, and 2-propanol were from
Fisher Scientific Co. Glaxo Wellcome Inc. (Toronto,
Ontario, Canada) provided the amprenavir, Merck and
Co. Inc. (Whitehouse Station, New Jersey, USA) pro-
vided the indinavir, and Abbott Laboratories (Abbott
Park, Illinois, USA) provided the ritonavir. The mouse
feed was obtained from Harlan Teklad Laboratory
(Madison, Wisconsin, USA). The triglyceride determi-
nation kit was from Wako Chemicals USA Inc. (Rich-
mond, Virginia, USA). The CD36 morpholino (5′-
ATGGGCTGTGACCGGAACTGTGGGC-3′) was from
GeneTools LLC (Philomath, Oregon, USA). The LDLR
and C57BL/6 mice came from The Jackson Laboratory
(Bar Harbor, Maine, USA). The CD36 null mice, apoE
null mice, and apoE/CD36 null mice were provided by
Maria Febbraio (Weill Medical College of Cornell Uni-
versity, New York, New York, USA). All the animals
were backcrossed into the C57BL/6 strain ten times.
Buffers. Sample buffer (5×) consisted of 0.31 M Tris (pH
6.8), 2.5% (wt/vol) SDS, 50% (vol/vol) glycerol, and 0.125%
(wt/vol) bromophenol blue. Tris-buffered saline (TBS)
consisted of 20 mM Tris (pH 7.6) and 137 mM NaCl.
Cell culture. THP-1 cells were grown in RPMI 1640
medium containing 10% FCS, 100 U/ml penicillin-
streptomycin, and 2 mM L-glutamine. The medium
was changed every 48 hours. THP-1 cells were also
grown in the presence of 100 nM PMA for 72 hours to
induce differentiation to a macrophage phenotype
(20). Human PBMCs were isolated as described (21).
Aggregated LDL (50 µg/ml) was added to the culture
medium as the source of exogenous modified LDL. To
prepare aggregated LDL, 2 mg freshly isolated LDL was
diluted in 1 ml PBS and vortexed for 60 seconds as
described by Khoo et al. (22). Mouse peritoneal
macrophages were isolated as described (23).
Cholesterol and cholesteryl ester mass quantification. Cho-
lesteryl heptadecanoate was added to each vessel prepa-
ration to serve as an internal standard and the samples
were then extracted with isopropanol-hexane (24). The
extracted lipid was derivatized by suspending the dried
lipid in N,O-bis(trimethylsilyl)trifluoroacetamide,
trimethylchlorosilane, and acetonitrile (89:1:10). The
material was heated at 80°C for 5 minutes, dried, sus-
pended in iso-octane, and used for gas chromatogra-
phy (Protocol T496125B, Supelco; Sigma-Aldrich).
Authentic cholesterol (Sigma-Aldrich) was dissolved in
iso-octane and used as a standard for the retention
time of cholesterol. The samples were injected (split-
less) into a 6890 gas chromatograph G2579A system
(Agilent Technologies, Palo Alto, California, USA)
equipped with an SGE HT5 aluminum-clad fused sili-
ca capillary column (12 m × 0.32 mm × 0.1 µm; Sigma-
Aldrich). The gas chromatography temperature pro-
gram was as follows: initial temperature was 220°C for
3 minutes. This was increased to 310°C (20°C in-
crease/min) and then to 400°C (10°C/min) and held
for 3.5 minutes. A mass-selective detector (model 5973;
Agilent Technologies) was used in both scan and select-
ed ion-monitoring modes to identify the samples.
SDS-PAGE and immunoblotting. Samples were concen-
trated by trichloroacetic acid precipitation and washed
in acetone. Pellets were suspended in sample buffer
containing 1.2% (vol/vol) β-mercaptoethanol and heat-
ed at 95°C for 3 minutes before being loaded onto gels.
Proteins were separated in a 12.5% SDS-polyacrylamide
gel using the method of Laemmli (25). The separated
proteins were then transferred to PVDF membranes.
Each membrane was blocked in TBS containing 5% dry
milk for 1 hour at room temperature. Primary anti-
bodies were diluted in TBS containing 1% dry milk and
incubated with the PVDF membrane for 1 hour at
room temperature. The PVDF membrane was washed
four times, 10 minutes each, in TBS plus 1% dry milk.
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The secondary antibodies (all conjugated to HRP) were
diluted 1:20,000 in TBS plus 1% dry milk and incubat-
ed with the PVDF membrane for 1 hour at room tem-
perature. The membrane was then washed and the
bands were visualized by chemiluminescence.
Quantification of atherosclerotic lesions. Six-week-old male
LDLR receptor (LDLR) null mice (The Jackson Labora-
tory) on a chow diet were given vehicle control (0.01%
ethanol) or the following protease inhibitors in their
drinking water: amprenavir (23 or 75 µg/mouse/day),
indinavir (25 or 75 µg/mouse/day), or ritonavir (10 or 50
µg/mouse/day). After 0, 4, or 8 weeks of treatment, plas-
ma was collected for quantification of cholesterol, cho-
lesteryl ester, and triglyceride. Six-week-old male apoE
null and apoE/CD36 double null mice were fed a chow
diet and given vehicle (0.01% ethanol) or ritonavir (10
µg/mouse/day) in their drinking water for 6 weeks. The
HDL cholesterol levels in all of the mice were 52 ± 9
mg/dl. The mice were then processed to quantify the sur-
face area of atherosclerotic lesions. To quantify the
lesions (26, 27), the aorta from the arch to the ileal bifur-
cation was collected, the extraneous tissue was dissected
away, and the intimal surfaces were exposed by a longi-
tudinal cut. The aortas were placed under a dissecting
microscope equipped with a CCD camera attachment
that captures the image in a computer file. Atheroscle-
rotic lesions on the intimal aortic surface appear as
bright white areas compared with the thin and translu-
cent aorta. Areas of intima covered by atherosclerotic
lesions were quantified with ImagePro software (Media
Cybernetics, Silver Spring, Maryland, USA).
Statistics. Least squares ANOVA was used to evaluate
the data with respect to sample, treatment, and time
using the ANOVA procedure of Statistica (StatSoft,
Tulsa, Oklahoma, USA). When appropriate, samples
were compared within a given time using the Tukey
HSD test. Means were considered different at P < 0.01. 
Results
HIV protease inhibitors induce THP-1 cells and human
PBMCs to accumulate cholesteryl esters. HIV protease
inhibitors are thought to influence the development of
cardiovascular disease primarily through increasing
plasma triglycerides and plasma cholesterol levels (7).
However, the direct effects of HIV protease inhibitors
on macrophages have not been examined in detail.
Because one of the prominent features of atheroscle-
rotic lesions is the presence of lipid-laden macrophages
(28), we determined whether HIV protease inhibitors
could directly affect the amount of cellular cholesterol
or cholesteryl esters associated with THP-1 cells, a
model human monocyte/macrophage cell line (20),
and with isolated human PBMCs. The cells were incu-
bated in the presence of 30 ng/ml of amprenavir, indi-
navir, ritonavir, or vehicle for 24 hours along with 50
µg/ml of aggregated LDL (an exogenous cholesterol
source), and then the total amounts of cholesterol and
cholesteryl esters associated with the cells were deter-
mined by gas chromatography (29). Figure 1a demon-
strates that only ritonavir treatment caused a signifi-
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Figure 1 
HIV protease inhibitors induce the accumulation of cholesteryl ester
in THP-1 macrophages and human PBMCs. The human mono-
cyte/macrophage cell line, THP-1, was cultured in 100 nM PMA for
72 hours to promote attachment and differentiation of the cells to
a macrophage phenotype. In addition, we used freshly isolated and
cultured human PBMCs (37) in these studies. The cells were incu-
bated in the presence of 10% serum and 50 µg/ml of aggregated LDL
along with 30 ng/ml of amprenavir, indinavir, ritonavir, or vehicle
(ethanol) for 24 hours. The cells were lysed, lipids extracted, and
processed to quantify total cellular cholesterol (a) or total cellular
cholesteryl ester (b) by gas chromatography. Bars represent mean ± SE,
n = 4 with triplicate measurements. *P < 0.01 compared with vehi-
cle, #P < 0.01 compared with amprenavir, +P < 0.01 compared with
indinavir. (c) THP-1 cells were lysed and 20 µg of protein was
resolved by SDS-PAGE and immunoblotted with antibodies for
CD36, SRA, and actin. Cross-reactive material was visualized by
chemiluminescence. The exposure time was 2 minutes. The data are
representative of five independent experiments. Essentially identical
immunoblots were generated with human PBMCs (data not shown).
cant increase in cellular free cholesterol. In contrast,
Figure 1b illustrates that compared with the vehicle
control (0.01% ethanol), each of the protease inhibitors
significantly increased the amount of cell-associated
cholesteryl ester. Interestingly, the increase in the
amount of cell-associated cholesteryl ester correlated
with the degree of dyslipidemia affiliated with the
drugs, with amprenavir causing the least increase, fol-
lowed by indinavir and then ritonavir (1, 30).
CD36 plays a role in HIV protease inhibitor–induced sterol
accumulation. Multiple mechanisms can alter cellular
cholesteryl ester levels, including new sterol synthesis
and uptake of exogenous sterol from lipoproteins. To
test whether HIV protease inhibitors were inducing new
sterol synthesis, THP-1 cells were treated with vehicle or
30 ng/ml of amprenavir, indinavir, or ritonavir in the
presence of [3H]acetate (31). The cells were then
processed to isolate sterols and the amount of new sterol
synthesized was determined by TLC (29). Each of the
treatment groups synthesized 42,000 ± 2,401 disinte-
grations per minute (dpm) sterol per mg cell protein per
24 hours, indicating that global sterol synthesis was not
altered. We next determined whether HIV protease
inhibitors altered the levels of CD36 and SRA, two recep-
tors involved in the uptake of exogenous lipoproteins
and the formation of foam cells (15). THP-1 cells were
treated as described above and analyzed by SDS-PAGE
and immunoblot. We found that CD36 protein levels
were increased in the presence of the HIV protease
inhibitors, whereas the levels of SRA were not affected
(Figure 1c). In addition, the relative increase in the level
of CD36 (with amprenavir, 3.4-fold; indinavir, 6.2-fold;
ritonavir, 13.1-fold) approximated the measured increase
in cholesteryl ester accumulation (compare Figure1b to
Figure 1c). The actin immunoblots indicate that equiv-
alent amounts of protein were applied to each lane.
To determine whether the increase in CD36 protein
levels played a role in the increase in cholesteryl ester
accumulation, CD36-blocking antibodies and a CD36
morpholino (which blocks transcription) were used.
Figure 2a demonstrates that the CD36 antibody cross-
reacts with a 90-kDa protein in CHO cells transfected
with cDNA encoding human CD36 but not with CHO
cells transfected with vector only. THP-1 cells contain
the same 90-kDa cross-reacting band, and important-
ly, THP-1 cells treated with the CD36 morpholino did
not produce the 90-kDa band. These data demonstrate
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Figure 2
CD36 blocking antibodies and a CD36 morpholino prevent the accu-
mulation of sterol. (a) THP-1 cells were cultured in 100 nM PMA for
72 hours to promote attachment and differentiation of the cells to
a macrophage phenotype and then treated with 25 nmol of a CD36
morpholino for 24 hours. The THP-1 cells and CHO cells expressing
human CD36 (hCD36) or the vector only were lysed and 20 µg of
protein was resolved by SDS-PAGE and immunoblotted with the
CD36 blocking antibody. Cross-reactive material was visualized by
chemiluminescence. The exposure time was 2 minutes. The data are
representative of three independent experiments. (b) THP-1 cells
were cultured in 100 nM PMA for 72 hours to promote attachment
and differentiation of the cells to a macrophage phenotype. The cells
were incubated in the presence of 10% serum and 50 µg/ml of aggre-
gated LDL, along with 30 ng/ml of amprenavir, indinavir, ritonavir,
or vehicle (ethanol) for 24 hours. In addition, different sets of cells
also contained one of the following: 20 µg/ml of CD36 blocking IgM,
20 µg/ml nonrelevant IgM, or a CD36 morpholino (25 nmol). After
the treatment period, the cells were lysed, lipids extracted, and
processed to quantify total cellular cholesterol and cholesteryl esters
by gas chromatography. Bars represent mean ± SE, n = 5 with tripli-
cate measurements. *P < 0.01 compared with vehicle, +P < 0.01 com-
pared with amprenavir, #P < 0.01 compared with indinavir.
Figure 3
Ritonavir does not induce sterol accumulation in peritoneal
macrophages isolated from CD36 null mice. Peritoneal macrophages
were isolated from the indicated mouse strains and then incubated
in the presence of 10% serum and 50 µg/ml of aggregated LDL, along
with 30 ng/ml of ritonavir or vehicle (0.01% ethanol) for 24 hours.
After the treatment period the cells were lysed, lipids extracted, and
processed to quantify total cellular cholesterol and cholesteryl esters
by gas chromatography. Bars represent mean ± SE, n = 3 with tripli-
cate measurements. *P < 0.01 compared with vehicle.
that the CD36-blocking antibody recognizes human
CD36 and that treatment with a CD36 morpholino
decreases CD36 protein below the level of detection.
THP-1 cells were then incubated in the presence of 30
ng/ml of amprenavir, indinavir, or ritonavir for 24
hours along with CD36-blocking antibodies (20
µg/ml), nonrelevant isotype–matched antibodies (20
µg/ml), or a CD36 morpholino (25 nmol). At the end
of the incubation period, the total amount of choles-
terol and cholesteryl esters associated with the cells was
determined by gas chromatography. Figure 2b demon-
strates that the nonrelevant IgM antibody did not
affect the ability of the protease inhibitors to induce
sterol accumulation. However, both the CD36-block-
ing antibody and the CD36 morpholino completely
inhibited the ability of the protease inhibitors to
induce sterol accumulation.
The use of blocking CD36 antibodies and a CD36
morpholino are pharmacological approaches to
demonstrate the involvement of CD36 in HIV pro-
tease–induced increases in macrophage cholesteryl
ester. To be certain that an increase in CD36 protein
levels is required for the increase in macrophage cho-
lesteryl esters, we isolated peritoneal macrophages
from various mouse models and then treated the iso-
lated cells with HIV protease inhibitors as described
above. After the treatment period the cells were
processed and the amount of cholesterol and choles-
teryl ester associated with the cells was quantified. Fig-
ure 3 demonstrates that treatment with vehicle (0.01%
ethanol) did not alter the level of sterol in macro-
phages isolated from any of the mouse strains. Macro-
phages isolated from C57BL/6, apoE null, and LDLR
null mice all accumulated sterol in response to treat-
ment with ritonavir. In contrast, macrophages isolat-
ed from mice lacking CD36 (CD36 null and apoE/
CD36 null mice) did not accumulate sterol in the pres-
ence of HIV protease inhibitors. These data strongly
support the conclusion that CD36 was required for
HIV protease inhibitor–induced increases in macro-
phage sterol levels.
HIV protease inhibitors promote the generation of lipid-laden
macrophages independent of dyslipidemia. The in vitro data
established that HIV protease inhibitors increase the
cellular level of macrophage cholesteryl esters in a
CD36-dependent manner. These data implied that
frank dyslipidemia is not necessary to generate lipid-
laden macrophages and subsequently atherosclerotic
lesions. To directly test this prediction, two doses of
amprenavir, indinavir, or ritonavir were given via the
drinking water to LDLR null mice for 0, 4, or 8 weeks.
The LDLR null mice were maintained on a normal
chow diet, thereby greatly alleviating diet-induced dys-
lipidemia and diet-induced atherosclerotic lesion for-
mation. The lower doses of protease inhibitors did not
alter plasma triglyceride (Figure 4a) or cholesterol/cho-
lesteryl ester (Figure 4b) levels, whereas the higher
doses of inhibitors induced a pronounced increase in
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Figure 4
Effect of HIV protease inhibitors on plasma lipids. Six-week-old male LDLR null mice on a chow diet were given vehicle control (0.01%
ethanol) or the following protease inhibitors in their drinking water: amprenavir (23 or 75 µg/mouse/day), indinavir (25 or 75
µg/mouse/day), or ritonavir (10 or 50 µg/mouse/day). The total plasma triglyceride (a) and cholesterol/cholesteryl ester (b) levels were
determined after 0, 4, and 8 weeks of treatment with a commercial kit (Wako Chemicals USA Inc.) or gas chromatography. Bars represent
mean ± SE, n = 8. *P < 0.01 compared with vehicle. White bars are vehicle controls, black bars are low-dose protease inhibitors, and gray
bars are high-dose protease inhibitors.
plasma triglyceride and cholesterol/cholesteryl ester
levels. These data demonstrate that we established
doses of HIV protease inhibitors that promote dyslipi-
demia and doses that do not promote dyslipidemia, in
the same animal model.
We next determined whether HIV protease inhibitors
altered the level of cholesterol/cholesteryl ester associ-
ated with macrophages in vivo by isolating peritoneal
macrophages (23) from the same group of mice
described above and quantifying the level of choles-
terol/cholesteryl ester by gas chromatography (29). All
three protease inhibitors induced an increase in the
level of peritoneal macrophage sterol compared with
vehicle-treated animals (Figure 5). Importantly, the
lower doses of protease inhibitors caused a dramatic
increase in macrophage sterol levels without a con-
comitant increase in plasma lipids (Figure 4), whereas
the higher doses increased plasma lipids (Figure 4) and
further increased macrophage sterol levels.
The in vitro data demonstrated that HIV protease
inhibitors increased the expression of CD36 in THP-1
cells. To determine whether HIV protease inhibitors
stimulated an increase in the level of macrophage
CD36 protein in vivo, we isolated peritoneal macro-
phages from LDLR null mice, generated cell lysates,
and analyzed the proteins by SDS-PAGE and immuno-
blotting. Figure 6a demonstrates that HIV protease
inhibitors did not alter the expression of SRA or actin.
However, the inhibitors dramatically increased the
amount of CD36 both at the low and high doses of
inhibitor. In addition, the relative increase in the level
of CD36 (with amprenavir, 3.1-fold; indinavir, 5.3-fold;
ritonavir, 12.9-fold) approximated the measured
increase in cholesteryl ester accumulation (see Figure
5). We next determined whether the HIV protease
inhibitors specifically affected macrophage CD36 pro-
tein levels or whether they also increased CD36 protein
levels in other tissues. We isolated cardiac myocytes,
adipocytes, and platelets and analyzed the levels of
CD36 by immunoblot. HIV protease inhibitors did not
alter the levels of CD36 in cardiac myocytes, adipocytes,
or platelets, suggesting that these compounds specifi-
cally alter CD36 levels in macrophages (Figure 6b).
Because HIV protease inhibitors induced macro-
phages to accumulate sterol, we next determined
whether HIV protease inhibitors promoted the for-
mation of atherosclerotic lesions. To directly deter-
mine this, two doses of amprenavir, indinavir, or
ritonavir were given in the drinking water to LDLR
null mice for 8 weeks. At the conclusion of the study,
the ascending and descending aortas were removed
and opened, and the areas covered by lesions were
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Figure 5
HIV protease inhibitors induce an increase in peritoneal macrophage
cholesterol/cholesteryl ester levels. Six-week-old male LDLR null mice
on a chow diet were given vehicle control (0.01% ethanol) or the fol-
lowing protease inhibitors in their drinking water: amprenavir (23 or
75 µg/mouse/day), indinavir (25 or 75 µg/mouse/day), or ritonavir
(10 or 50 µg/mouse/day). After 8 weeks of treatment, peritoneal
macrophages were isolated and cholesterol/cholesteryl ester mass
was determined by gas chromatography. Bars represent mean ± SE,
n = 8. *P < 0.01 compared with vehicle, #P < 0.01 compared with low
dose of the same protease inhibitor.
Figure 6
HIV protease inhibitors induce an increase of CD36 protein levels in
peritoneal macrophages. Six-week-old male LDLR null mice on a chow
diet were given vehicle control (0.01% ethanol) or the following pro-
tease inhibitors in their drinking water: amprenavir (23 or 75
µg/mouse/day), indinavir (25 or 75 µg/mouse/day), or ritonavir (10
or 50 µg/mouse/day). (a) After 8 weeks of treatment, peritoneal
macrophages were isolated, the cells were lysed, and 20 µg of protein
was resolved by SDS-PAGE and immunoblotted with antibodies for
CD36, SRA, and actin. The data are representative of eight mice. (b)
After 8 weeks of treatment, cardiac myocytes (38), adipocytes (39),
and platelets (40) were isolated, the cells were lysed, and 20 µg of pro-
tein was resolved by SDS-PAGE and immunoblotted with antibodies
against CD36. The data are representative of eight mice.
quantified by image analysis (26, 27). All of the ani-
mals treated with HIV protease inhibitors had signif-
icantly greater lesion area than did vehicle-treated ani-
mals (Figure 7). Animals treated with amprenavir had
the smallest increase in lesion area and those treated
with ritonavir had the largest increase in lesion area,
consistent with the relative increase observed for
CD36 and sterol levels in peritoneal macrophages. In
addition, the higher doses of protease inhibitors
caused an additional increase in lesion area compared
with lower doses of the same protease inhibitors.
The data suggested that HIV protease inhibitors
induced the upregulation of macrophage CD36,
which then promoted the formation of atherosclerot-
ic lesions independent of dyslipidemia. To directly test
whether the increase in CD36 was responsible for the
increase in atherosclerotic lesion formation, apoE null
and apoE × CD36 double null mice were fed a chow
diet and given vehicle or ritonavir (10 µg/mouse/day)
in their drinking water for 6 weeks. The dose of riton-
avir used did not induce dyslipidemia greater than
that seen in vehicle-treated mice (data not shown). At
the conclusion of the study, atherosclerotic lesion area
was quantified in the ascending and descending aor-
tas by image analysis (Figure 8). Vehicle-treated apoE
null and apoE × CD36 double null mice had relatively
small lesions, and importantly, the extent of the
lesions was similar in both types of animals. Ritonavir-
treated apoE null mice had a substantial increase in
lesion area compared with vehicle-treated control
mice. In contrast, ritonavir did not induce atheroscle-
rotic lesions in apoE × CD36 double null mice.
HIV protease inhibitors increase CD36 and PPAR-γmRNA
in a PKC-dependent manner. Previous studies have
demonstrated that CD36 expression can be upregu-
lated through activation of the transcription factor
PPAR-γ (32). In addition, earlier studies have demon-
strated that PKC is involved in the pathway responsi-
ble for the upregulation of CD36 expression (33). To
determine whether ritonavir induced an increase in
CD36 and PPAR-γ expression in a manner dependent
on PKC, we treated human PBMCs as indicated and
analyzed the amount of CD36 and PPAR-γ mRNA by
Northern blot. Figure 9 demonstrates that ritonavir or
aggregated LDL by themselves did not alter CD36 or
PPAR-γ mRNA levels; however, the combination of
ritonavir and aggregated LDL increased CD36 mRNA
levels by 22-fold and PPAR-γ levels by 18-fold. Diacyl-
glycerol (DAG) (20 µM) and PMA (100 nM), activators
of PKC, stimulated an increase in CD36 and PPAR-γ
mRNA independent of ritonavir. Importantly, two 
different PKC inhibitors, Go6976 (500 nM) and
calphostin C (200 nM), inhibited the ability of riton-
avir to increase CD36 and PPAR-γmRNA. Finally, two
different PPAR-γactivators, 15d-PGJ2 (1 µM) and cigli-
tazone (13 µM), stimulated the expression of CD36
and PPAR-γmRNA, and the increase in expression was
blocked by PKC inhibitors.
Discussion
The clinical data suggest that HIV protease inhibitors
may promote accelerated atherosclerosis (6, 34, 35), and
the current data provide one possible mechanism for
this acceleration. Our studies demonstrate that three
different HIV protease inhibitors, ritonavir, indinavir,
and amprenavir, can increase the level of CD36 protein
and the level of cholesteryl ester in THP-1 macrophages
and human PBMCs. Importantly, the increase in cho-
lesteryl ester accumulation was eliminated in the pres-
ence of CD36-blocking antibodies and a CD36 mor-
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Figure 7
HIV protease inhibitors induced the formation of atherosclerotic
lesions in LDLR null mice. Six-week-old male LDLR null mice on a
chow diet were given vehicle control (0.01% ethanol) or the follow-
ing protease inhibitors in their drinking water: amprenavir (23 or 75
µg/mouse/day), indinavir (25 or 75 µg/mouse/day), or ritonavir (10
or 50 µg/mouse/day). These mice were then used to quantify the sur-
face area of atherosclerotic lesions. To quantify lesions, we first
removed the aorta from the arch to the ileal bifurcation and dissect-
ed away extraneous tissue. The intimal surfaces were exposed by a
longitudinal cut. The aortas were placed under a dissecting micro-
scope equipped with a video camera attachment that captures the
image in a computer file. Atherosclerotic lesions on the intimal aor-
tic surface appear as bright white areas compared with the thin and
translucent aorta. Areas of intima covered by atherosclerotic lesions
were quantified with ImagePro software. This software analyzes dif-
ferences in contrast to identify areas covered by lesions. Bars repre-
sent mean ± SE, n = 8. *P < 0.01 compared with vehicle, #P < 0.01
compared with low dose of the same protease inhibitor.
Figure 8
Ritonavir did not induce formation of atherosclerotic lesions in 
apoE × CD36 null mice. Six-week-old male apoE null and apoE × CD36
double null mice were fed a chow diet and given vehicle (0.01%
ethanol) or ritonavir (10 µg/mouse/day) in their drinking water for
6 weeks. At the conclusion of the study the extent of atherosclerotic
lesions was quantified as above. Data are presented as mean ± SE. 
n = 12. *P < 0.01 compared with vehicle.
pholino. Furthermore, peritoneal macrophages isolat-
ed from CD36 null mice did not accumulate sterol,
whereas peritoneal macrophages isolated from CD36
wild-type mice did accumulate sterol, thereby demon-
strating that the increase in CD36 was responsible for
the increase in cellular cholesterol. In addition, the rel-
ative increase in CD36 protein levels correlated with the
relative increase in cholesteryl ester levels, further impli-
cating CD36 as a target for HIV protease inhib
itor–induced changes. These in vitro data demonstrate
that HIV protease inhibitors have direct effects on
macrophage sterol regulation.
To determine whether the in vitro findings were rele-
vant in vivo, we treated LDLR null mice with two dif-
ferent doses of HIV protease inhibitors. The doses for
ritonavir, indinavir, and amprenavir were titrated to
produce models that develop dyslipidemia as judged by
an increase in plasma triglycerides and sterol levels. In
addition, we titrated the doses for each protease
inhibitor so they did not cause dyslipidemia. These
models allowed us to elucidate the effects of three dif-
ferent HIV protease inhibitors in the absence of frank
dyslipidemia. The use of the LDLR null mouse model
was critical for these studies because LDLR null mice
do not develop extensive atherosclerotic lesions when
fed a chow diet, thereby allowing us to determine the
effects of HIV protease inhibitors on the development
of atherosclerotic lesions.
A major novel finding of these studies is that doses
of HIV protease inhibitors that do not cause dyslipi-
demia cause an increase in the amount of CD36 and
cholesterol/cholesteryl ester associated with peritoneal
macrophages. Importantly, these same doses of HIV
protease inhibitors cause a significant increase in ath-
erosclerotic lesion area without an increase in plasma
lipid levels. Interestingly, the higher doses of HIV pro-
tease inhibitors caused more of an increase in athero-
sclerotic lesion area, probably as a result of lipidemia
that developed after treatment, although this has not
been directly demonstrated. Finally, we used another
animal model of atherosclerosis, the apoE null and the
apoE × CD36 double null mice, to determine whether
the increase in CD36 levels was responsible for the
increase in atherosclerotic lesion formation. At doses
of protease inhibitors that did not induce dyslipi-
demia, apoE mice developed significant lesions, where-
as apoE × CD36 double null mice did not develop
lesions. Taken together, the data support the hypoth-
esis that HIV protease inhibitor–induced increases in
CD36 promote atherosclerotic lesion formation inde-
pendent of dyslipidemia.
In an initial attempt to understand how HIV protease
inhibitors stimulate the upregulation of CD36 protein
levels, we examined the effects of ritonavir on PPARs,
transcription factors that have been shown to increase
CD36 expression (32). Our data demonstrate that
ritonavir in the presence of aggregated LDL can induce
the expression of PPAR-γ and CD36 mRNA in a PKC-
dependent manner. It is not clear how HIV protease
inhibitors induce an alteration in the level of
macrophage CD36 without inducing a change in CD36
levels in platelets, cardiac myocytes, or adipocytes.
Although our data suggest that the upregulation of
PPAR-γ is responsible for the increase in CD36 protein
levels, contributions by other regulatory mechanisms
have not been ruled out. For instance, ritonavir has
been demonstrated to affect the levels of a different
transcription factor, SREBP-1, in the liver and
adipocytes, resulting in an increase in fatty acid and
sterol biosynthesis (2). Alternatively, the protease
inhibitors may be preventing the degradation of CD36
and thereby increasing the total cellular mass of the
protein. Liang et al. (36) recently demonstrated that
ritonavir protects apoB from degradation by protea-
somes in the liver. Although many of these other stud-
ies examined only ritonavir, the experiments we report
here used three different protease inhibitors, which
suggests that the results reflect an effect of HIV pro-
tease inhibitors as opposed to the nonspecific effect of
a single compound.
A major novel aspect of these studies is the establish-
ment of a mechanistic link between a clinically relevant
treatment for HIV and a significant detrimental side
effect of using these protease inhibitors in patients.
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Figure 9
Ritonavir increases CD36 and PPAR-γ mRNA in a PKC-
dependent manner. Human PBMCs were incubated in the
presence of 10% serum and 50 µg/ml aggregated LDL
(agLDL) and/or 30 ng/ml ritonavir as indicated for 24 hours.
In addition, some sets of cells were also treated with PMA
(100 nM), (diacylglycerol [DAG]; 20 µM), Go6976 (500
nM), calphostin C (200 nM), 15d-PGJ2 (1 µM), or ciglita-
zone (13 µM). The cells were then lysed, mRNA was isolated,
and the relative amounts of CD36, PPAR-γ, and GAPDH
mRNA were determined by Northern analysis. Shown are rep-
resentative data from three independent experiments.
Although it is difficult to extend animal studies to
humans, these studies strongly suggest that caution
should be used when monitoring the effects of HIV
protease inhibitors in patients because atherosclerosis
may be promoted without a corresponding increase in
marker plasma lipids. A more useful test may be to
screen PBMCs from patients for an increase in CD36.
Future studies will focus on the complex issue of how
HIV protease inhibitors specifically increase CD36 lev-
els in macrophages.
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